For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230310:nRSJ5979Sa&default-theme=true
RNS Number : 5979S CVS Group plc 10 March 2023
10 March 2023
CVS Group Plc
("CVS" or the "Company")
Exercise of SAYE Options, PDMR Dealing
and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services,
announces that on 10 March 2023, options over a total of 1,667 ordinary shares
of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group
2019 SAYE Plan (2019/2023), at an exercise price of £8.63 (the "SAYE
Exercise").
The sum of 1,667 Ordinary shares were satisfied from the shares held in the
Employee Benefit Trust managed by JTC Group. As a result, no new Ordinary
Shares were issued to satisfy the SAYE Exercise.
Ben Jacklin, Chief Operating Officer exercised options over 709 Ordinary
Shares in the Company. The balance of the options were exercised by certain
other employees and former employees of the Company.
Following his option exercise, Ben Jacklin holds a beneficial interest in
23,093 Ordinary Shares in the Company, representing approximately 0.032 per
cent of the total voting rights of the Company, calculated on the same basis.
Following the SAYE Exercise, the Company has a total issued share capital of
71,385,048 Ordinary Shares each carrying one voting right. The Company holds
no Ordinary Shares in treasury. Therefore, the total number of voting rights
in the Company will be 71,385,048. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.
Contacts:
CVS Group
plc
via Camarco
Richard Fairman, CEO
Jenny Farrer, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker)
+44
(0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker)
+44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial
PR)
Geoffrey Pelham-Lane
+44 (0)7733 124 226
Ginny
Pulbrook
+44 (0)7961 315 138
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Ben Jacklin
2 Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name CVS Group plc
b) LEI 213800J41XDQ2NX48O05
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 0.2 pence each
Identification code GB00B2863827
b) Nature of the transaction Exercise of options under the 2019 SAYE Plan (1 January 2023 maturity)
c) Price(s) and volume(s) Price(s) Volume
£8.63 709
d) Aggregated information
- Aggregated volume
N/A - single transaction
- Price
e) Date of the transaction 10 March 2023
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A - single transaction
e)
Date of the transaction
10 March 2023
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHJMMMTMTJBBAJ